A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3717-3727

  Rademaker Lakhai, Jeany M ^a,b   Van Den Bongard, Desiree ^a,b   Pluim, Dick ^a   Beijnen, Jos H ^a,b,c   Schellens, Jan H M ^a,b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIMETHYL SULFOXIDE; GRANISETRON; IMIDAZOLIUM DIMETHYL SULFOXIDE IMIDAZOLE TETRACHLORORUTHENATE; RUTHENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLISTER; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTINUOUS INFUSION; DIARRHEA; DOSE LIMITING TOXICITY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TOXICITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERKALEMIA; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; LEUKOCYTE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS INHIBITION; NAUSEA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; THROMBOSIS; TINNITUS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DIMETHYL SULFOXIDE; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, CHEMICAL; ORGANOMETALLIC COMPOUNDS; RUTHENIUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 2542625358     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0746     Document Type: Article

References (34)

1. Reedijk J. Medicinal applications of heavy-metal compounds. Curr Opin Chem Biol 1999;3:236-40.
2. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995;13:228-44.
3. Sava G, Bergamo A. Ruthenium based compounds and tumor growth control (review). Int J Oncol 2000;17:353-65.
4. Sava G. Ruthenium compounds in cancer therapy, In: Fricker SP, editor, Metal compounds in cancer therapy, chapter 4. London: Chapman and Hall; 1994. p. 65-91.
5. Sava G, Zorzet S, Giraldi T, Mestroni G, Zassinovich G. Antineo-plastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms. Eur J Cancer Clin Oncol 1984;20:841-7.
6. Srivastava SC, Richard P, Meinken GE, Larson SM, Grunbaum Z. Tumor uptake of radioruthenium compounds. In: Spencer RP, editor. Radiopharmaceuticals-structure-activity relationships. New York: Grune and Stratton Inc; 1981. p. 207-23.
7. Srivastava SC, Mausner LF, Clarke MJ. Radioruthenium-labeled compounds for diagnostic tumor imaging. In: Baulieu E, Forman DT, Sundberg MI, et al., editors. Progress in clinical biochemistry and medicine, vol 10. Berlin/Heidelberg, Germany: Springer-Verlag; 1989. p. 112-49.
8. Clarke M. J. Oncological implications of the chemistry of ruthenium. In: Sigel A, Sigel H, editors. Metal ions in biological systems. New York: Marcel Dekker 1979. p. 231-83.
9. 4(DMSO)Im] in the mouse. Clin Exp Metastasis 1994;12:93-100.
10. 4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors. Anti-Cancer Drugs 1999;10:129-38.
11. Sava G, Gagliardi R, Bergamo A, Alessio E, Mestroni G. Treatment of metastases of solid mouse tumors by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine. Anticancer Res 1999;19:969-72.
12. Bergamo A, Gagliardi R, Scarcia V, et al. In vitro cell cycle arrest, in vivo action of solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther 1999;289:559-64.
13. Bergamo A, Zorzet S, Gaba B, et al. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. Anti-Cancer Drugs 2000;11:667-72.
14. Zorzet S, Bergamo A, Cocchietto M, et al. Lack of in vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict in vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther 2000;295:927-33.
15. Sava G, Bergamo A, Cocchietto M, et al. Interaction of NAMI-A with the regulation of cell cycle progression (abstract 501). Clin Cancer Res 2000;6:4566s.
16. Sava G, Capozzi I, Clerici V, Gagliardi G, Alessio E, Mestroni G. Pharmacological control of lung metastases of solid tumors by a novel ruthenium complex. Clin Exp Metastasis 1998;16:371-9.
17. Vacca A, Bruno M, Boccarelli A, et al. Inhibition of endothelial cell function and of angiogenesis by the metastasis inhibitor NAMI-A. Br. J Cancer 2002;86:993-8.
18. 4(DMSO)Im]. Selective inhibition of spontaneous lung metastasis by the ruthenium complex. Drug Investig 1994;8:150-61.
19. 4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin Exp Metastasis 1992;10:273-80.
20. Sava G, Alessio E, Bergamo A, Mestroni G. Sulfoxide ruthenium complexes: non-toxic tools for the selective treatment of solid tumor metastases. In: Clarke MJ, Sadler PJ, editors. Biological inorganic chemistry: vol 1, Berlin, Germany: Springer-Verlag; 1999.
21. Concchietto M, Sava G. Blood concentration and toxicity of the antimetastatic agent NAMI-A following repeated intravenous treatment in mice. Pharmacol And Toxicol 2000;87:193-7.
22. Sava G, Cocchietto M. Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy beagle dogs. In Vivo 2000;14:741-4.
23. Bouma M, Nuijen B, Sava G, et al. Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A. Int J Pharm 2002;248:247-59.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
25. Division of Cancer Treatment and Diagnosis, National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda MD: National Cancer Institute; 1988.
26. Crul M, Van den Bongard HJ, Tibben MM, et al. Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 2001;369:442-5.
27. Ma J, Verweij J, Planting AS, et al. Current sampling handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Br J Cancer 1995;71:512-7.
28. 2P-postlabeling assay for the quantitation of the major platinum-DNA adducts. Anal Biochem 1999;275:30-8.
29. Miller SA, Dykes DD, Polesky HFA. Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
30. Cocchietto M, Sava G. Blood kinetics and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. Pharmacol Toxicol 2000;87:193-7.
31. 4 and related complexes. Nicolini M, editor. Platinum and other metal coordination compounds in cancer chemotherapy. Boston: M. Nijhoff; 1988. p. 617-633.
32. 2 in chinese hamster ovary cells in vitro. Chem Biol Interact 1986;59:247-54.
33. Mestroni G, Alessio E, Calligaris M, et al. Chemical, biological and antitumor properties of ruthenium (II) complexes with dimethylsulphoxide. In: Baulieu E, Forman DT, Sundberg MI, et al., editors. Progress in clinical biochemistry and medicine, vol 10. Berlin/Heidelberg: Springer-Verlag, 1989. p. 71-87.
34. Novakova O, Kasparkova J, Vrana O, Van Vliet PM, Reedijk J, Brabec V. Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Biochemistry, 1995;34:12369-78.